1
Omid C Farokhzad, Sangyong Jon, Robert S Langer: Controlled release polymer nanoparticle containing bound nucleic acid ligand for targeting. Massachusetts Institute of Technology, Lahive & Cockfield, Brian C Trinque, June 23, 2009: US07550441 (53 worldwide citation)

The present invention relates to a conjugate that includes a nucleic acid ligand bound to a controlled release polymer system, a pharmaceutical composition that contains the conjugate, and methods of treatment using the conjugate. The controlled release polymer system includes an agent such as a the ...


2
Omid C Farokhzad, Sang Yong Jon, Robert S Langer: Controlled release nanoparticle having bound oligonucleotide for targeted delivery. Massachusetts Institute of Technology, Lahive & Cockfield, Brian C Trinque, June 1, 2010: US07727969 (46 worldwide citation)

The present invention relates to a conjugate that includes a nucleic acid ligand bound to a controlled release polymer system, a pharmaceutical composition that contains the conjugate, and methods of treatment using the conjugate. The controlled release polymer system includes an agent such as a the ...


3
James D Rodgers, Argyrios G Arvantis, Jack Guoen Shi, Stacey Shepard: Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. Incyte Corporation, Lahive & Cockfield, Brian C Trinque, Pankaj N Desai, November 16, 2010: US07834022 (38 worldwide citation)

The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related ...


4

5
Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai Yuen Yue, James D Rodgers, Haisheng Wang: Processes for preparing JAK inhibitors and related intermediate compounds. Incyte Corporation, Lathrop & Gage, Brian C Trinque, April 2, 2013: US08410265 (28 worldwide citation)

The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein t ...


6
James D Rodgers, Hui Yin Li: Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. Incyte Corporation, Lathrop & Gage, Brian C Trinque, May 13, 2014: US08722693 (22 worldwide citation)

The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, imm ...


7
Tarek A Zeidan, Scott Duncan, Christopher P Hencken, Thomas Andrew Wynn, Carlos N Sanrame: Prodrugs of fumarates and their use in treating various diseases. Alkermes Pharma Ireland, Lathrop & Gage, Brian C Trinque, March 11, 2014: US08669281 (22 worldwide citation)

The present invention provides compounds of formula (I), wherein: R1 is unsubstituted C1-C6 alkyl; La is substituted or unsubstituted C1-C6 alkyl linker, substituted or unsubstituted C3-C10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 hetero ...


8
James D Rodgers, Hui Yin Li: Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. Incyte Corporation, Lathrop & Gage, Brian C Trinque, September 9, 2014: US08829013 (20 worldwide citation)

The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, imm ...


9
George D Hartman, Osvaldo A Flores: Hepatitis B antiviral agents. Novira Therapeutics, Lathrop & Gage, Brian C Trinque, January 14, 2014: US08629274 (12 worldwide citation)

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.


10
William Williams: N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof. Inotek Pharmaceuticals Corporation, Lahive & Cockfield, Jane E Remillard, Brian C Trinque, January 5, 2010: US07642250 (12 worldwide citation)

The present invention relates to N-Benzyl-Substituted Pyridyl Porphyrin Compounds and compositions comprising an effective amount of N-Benzyl-Substituted Pyridyl Porphyrin Compounds. The N-Benzyl-Substituted Pyridyl Porphyrin Compounds include compounds of the following formula: wherein: M is Fe or ...